Abstract
The potential risk of drug‐induced prolongation of the electrocardiographic QT interval has been a clinical concern with some drug classes due to the increased risk of developing a rare but life‐threatening atypical ventricular tachycardia known as torsades de pointes. This has led to the withdrawal of several drugs from the U.S. market, as well as a Drug Safety Communication issued by the Food and Drug Administration for citalopram, which is commonly prescribed off‐label for management of anxiety in patients with post‐traumatic stress disorder (PTSD).
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.